Alaunos Therapeutics (TCRT) Competitors $2.88 -0.20 (-6.49%) As of 09:31 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TCRT vs. ELEV, SNYR, DRRX, LGVN, JATT, LPCN, CING, COCP, MRKR, and PMNShould you be buying Alaunos Therapeutics stock or one of its competitors? The main competitors of Alaunos Therapeutics include Elevation Oncology (ELEV), Synergy CHC Corp. (Uplisting) (SNYR), DURECT (DRRX), Longeveron (LGVN), JATT Acquisition (JATT), Lipocine (LPCN), Cingulate (CING), Cocrystal Pharma (COCP), Marker Therapeutics (MRKR), and ProMIS Neurosciences (PMN). These companies are all part of the "pharmaceutical products" industry. Alaunos Therapeutics vs. Its Competitors Elevation Oncology Synergy CHC Corp. (Uplisting) DURECT Longeveron JATT Acquisition Lipocine Cingulate Cocrystal Pharma Marker Therapeutics ProMIS Neurosciences Alaunos Therapeutics (NASDAQ:TCRT) and Elevation Oncology (NASDAQ:ELEV) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, community ranking, dividends and earnings. Do analysts prefer TCRT or ELEV? Elevation Oncology has a consensus target price of $3.39, indicating a potential upside of 790.98%. Given Elevation Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Elevation Oncology is more favorable than Alaunos Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alaunos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Elevation Oncology 0 Sell rating(s) 11 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do insiders & institutionals believe in TCRT or ELEV? 27.7% of Alaunos Therapeutics shares are owned by institutional investors. Comparatively, 83.7% of Elevation Oncology shares are owned by institutional investors. 16.1% of Alaunos Therapeutics shares are owned by insiders. Comparatively, 8.1% of Elevation Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more risk & volatility, TCRT or ELEV? Alaunos Therapeutics has a beta of -1.08, meaning that its stock price is 208% less volatile than the S&P 500. Comparatively, Elevation Oncology has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500. Does the MarketBeat Community prefer TCRT or ELEV? Elevation Oncology received 32 more outperform votes than Alaunos Therapeutics when rated by MarketBeat users. Likewise, 61.90% of users gave Elevation Oncology an outperform vote while only 58.33% of users gave Alaunos Therapeutics an outperform vote. CompanyUnderperformOutperformAlaunos TherapeuticsOutperform Votes758.33% Underperform Votes541.67% Elevation OncologyOutperform Votes3961.90% Underperform Votes2438.10% Does the media refer more to TCRT or ELEV? In the previous week, Elevation Oncology had 30 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 33 mentions for Elevation Oncology and 3 mentions for Alaunos Therapeutics. Alaunos Therapeutics' average media sentiment score of 0.97 beat Elevation Oncology's score of -0.04 indicating that Alaunos Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alaunos Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elevation Oncology 0 Very Positive mention(s) 2 Positive mention(s) 14 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is TCRT or ELEV more profitable? Elevation Oncology's return on equity of -59.73% beat Alaunos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Alaunos TherapeuticsN/A -267.77% -209.18% Elevation Oncology N/A -59.73%-40.05% Which has stronger valuation & earnings, TCRT or ELEV? Alaunos Therapeutics has higher revenue and earnings than Elevation Oncology. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlaunos Therapeutics$11K429.38-$35.14MN/AN/AElevation OncologyN/AN/A-$45.70M-$0.82-0.46 SummaryElevation Oncology beats Alaunos Therapeutics on 9 of the 13 factors compared between the two stocks. Get Alaunos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TCRT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TCRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TCRT vs. The Competition Export to ExcelMetricAlaunos TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.72M$6.92B$5.61B$8.62BDividend YieldN/A2.54%5.28%4.17%P/E RatioN/A8.6727.1419.96Price / Sales429.38262.53414.30157.63Price / CashN/A65.8538.2534.64Price / Book0.736.597.074.69Net Income-$35.14M$143.75M$3.23B$248.14M7 Day Performance-4.95%0.67%0.71%0.91%1 Month PerformanceN/A11.92%9.65%5.71%1 Year Performance-70.60%4.33%32.07%14.71% Alaunos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TCRTAlaunos Therapeutics1.2028 of 5 stars$2.88-6.5%N/A-69.4%$4.72M$11K0.0040ELEVElevation Oncology3.4138 of 5 stars$0.30-2.7%$3.39+1,017.4%-88.7%$18.00MN/A-0.3740Trending NewsAnalyst ForecastShort Interest ↓Analyst RevisionSNYRSynergy CHC Corp. (Uplisting)3.9509 of 5 stars$1.94+10.2%$10.00+415.5%N/A$17.84M$33.59M0.0040News CoveragePositive NewsDRRXDURECT1.3775 of 5 stars$0.57+7.0%N/A-59.0%$17.70M$1.86M-0.9380Positive NewsLGVNLongeveron3.5443 of 5 stars$1.20-4.4%$8.67+625.2%-27.1%$17.69M$2.23M-0.1920Gap DownJATTJATT AcquisitionN/A$1.01flatN/A-67.1%$17.42MN/A0.003High Trading VolumeLPCNLipocine2.3339 of 5 stars$3.25-0.9%$9.00+176.9%-60.3%$17.22M$3.67M-4.2410News CoverageAnalyst ForecastAnalyst RevisionCINGCingulate1.9721 of 5 stars$4.00+0.5%$26.00+549.8%+535.7%$16.99MN/A-0.4720Short Interest ↑Gap DownCOCPCocrystal Pharma2.6812 of 5 stars$1.67+0.9%$7.00+320.4%-45.0%$16.93MN/A-0.9010Short Interest ↑MRKRMarker Therapeutics4.2984 of 5 stars$1.51+7.0%$13.17+772.5%-57.8%$16.92M$6.59M-1.1260PMNProMIS Neurosciences2.3648 of 5 stars$0.52+3.0%$4.50+773.8%-69.0%$16.84MN/A-5.155Gap Up Related Companies and Tools Related Companies Elevation Oncology Alternatives Synergy CHC Corp. (Uplisting) Alternatives DURECT Alternatives Longeveron Alternatives JATT Acquisition Alternatives Lipocine Alternatives Cingulate Alternatives Cocrystal Pharma Alternatives Marker Therapeutics Alternatives ProMIS Neurosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TCRT) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alaunos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alaunos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
